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Introduction
Vitamin B12 (cobalamin) plays an important role in the formation of red blood cells and in the maintenance of neuronal function [1] . Its deficiency can lead to a wide spectrum of hematological and neuro-psychological disorders that can be reversed by early diagnosis and prompt treatment [1, 2] . As the conversion of methylmalonyl-coenzyme A (CoA) to succinyl-CoA is a vitamin B12 dependent reaction in humans [3, 4] , an elevated plasma level of methylmalonic acid (MMA) is a sensitive biomarker of vitamin B12 deficiency [5] [6] [7] , more accurately reflecting functional vitamin B12 deficiency than plasma B12 concentration itself [7, 8] . Large clinical studies have identified a 2.5th-97.5th percentile reference limit of MMA for middle-aged subjects (age 47-49 years) of 0.10-0.28 µmol/L serum and for elderly subjects (71-74 years) of 0.10-0.36 µmol/L [6, 9] . Pregnant women have had mean MMA 0.10 µmol/L (95% CI 0.10-0.11), newborns had 0.27 (0.26-0.28) and 6 month old infants 0.52 (0.46-0.59) µmol/L, respectively [10] . Different techniques, most frequently including GC-MS, capillary electrophoresis and high pressure liquid chromatography (HPLC) coupled to tandem mass spectrometry (LC-MS/MS), have been used to measure MMA in clinical applications [11] [12] [13] [14] . Conventional GC-MS methods require laborious extraction and derivatization to a non-polar form prior to a slow reverse-phase chromatographic separation to resolve structurally related compounds.
Although LC-MS/MS is rapidly replacing GC-MS in clinical laboratories due to its relative methodological simplicity [13] [14] [15] [16] [17] most current LC-MS/MS methods for MMA determination still use derivatization [13] [14] [15] [16] and few utilize automation. Our goal was to simplify and automate preanalytical handling and to speed separation to increase throughput, while retaining accuracy and precision in a routine clinical setting.
Analytical methods

Materials and samples
A homogeneous pool of sera from 200 healthy volunteers was available at the laboratory and used as matrix for calibrator solutions. Anonymized normal and patient serum samples from the Department of Clinical Chemistry, Helsingborg Hospital, Sweden, collected in SST tubes (Becton Dickinson) and centrifuged at 3000 rpm (1770 g) for 10 min. and saved as aliquots 
Preparations of calibrators and internal standard
Extraction of MMA and MMA-d3 from serum
The entire sample handling procedure, from sample application, to dissolution of extracted MMA and MMA-d3 is performed by a robotic pipetting system (Fredom EVO, TECAN) at room temperature, with barcode labeling of samples and plates to ensure sample tracking.
150µL sample is mixed well with 300µL MMA-d3 working solution in a 0.80 mL 96-well plate. A 300µL portion of each sample is robotically pipetted to a strong solid-phase anionexchanger (SAX-SPE) (Isolute ® ) that has been pre-wetted with 0.50 mL methanol followed by 0.50 mL water for 5 min each. MMA and MMA-d3 bound on the strong anion exchanger is washed first with 0.50 mL water followed by 0.50 mL methanol for 5 min each, and then 
Quantitative mass spectrometric analysis
An 8µL aliquot of each sample is automatically injected from the 96-well sample collecting plate into the HPLC Acquity system with a BEH-amide column (No. 186004800, 2.1 mm x 50 mm, 1.7 μm particle size, Waters) and separation of MMA and succinic acid is achieved in a mobile phase composed of solvent A (100% acetonitrile) and solvent B (100 mmol/L ammonium acetate, adjusted to pH 4.5 with formic acid) under a gradient process, as shown in Table I . MMA and MMA-d3 are passed essentially simultaneously at ca 0.80 min. followed by succinic acid at 1.16 min. to a Waters Quatro Micro tandem mass spectrometer equipped with the atmospheric pressure ionization (API) probe operating in negative mode. The 
Method validation
The five calibrator solutions and two serum controls are included in each analytical run. 
Results
Analytical characteristics
The typical peaks of MMA, MMA-d3 and succinic acid are shown in Figure 1 Calculations from typical analyses demonstrate the number of theoretical plates to be 625 for MMA and 5330 for succinic acid with a resolution of 3,25 for the separation. During method development, MMA levels in serum, EDTA-and heparin-plasma were determined, with no systematic differences in results (data not shown).
Method validation
Linearity: Calibration curves are consistently linear with MMA (µmol/L) = 1.28 X AUC (95% CI: 1.25 -1.31) + 0.007 (95% CI: -0.001 -0.015), and r 2 = 1.00 (95% CI: 0.999 -1.00) (N = 20). Quantification is based on comparison of the peak areas for MMA and MMA d3 Figure 2C, n=30) , the regression equation is y=0.99x + 0.01 (r 2 =0.99). The difference between our result and the mean value from > 36 other laboratories within the DEKS proficiency testing program for multiple samples with mean concentrations from 0.14 to 1.25 µmol/L has been -0.025 to 0.045 (µmol/L), and always < 2 SD from the mean (Figure 3 ). In the present method, the low background contributes also to the accuracy of the measurements. Analysis of samples containing from 0.1 to 0.5 µmol/L MMA are stable during storage at 4 ºC for 5 days Y=0.99X, R2 = 0.99). And no significant differences in results are seen after dilution of samples with initial volumes > 100 µL to 150 µL with 0.9% saline solution, or use of 100 µL, 160 µL or 320 µL serum samples. 150µL serum has been selected for the standard protocol.
Discussion
Despite significant interest and high demand for MMA determination in clinical chemistry, its application in most clinical laboratories is still a challenge due to the low endogenous concentration of MMA and potential interference from its isomer, succinic acid. The latter is considerably more abundant than MMA in human serum and difficult to remove. For many years, the GC-MS method has been considered as a golden standard for MMA determination [18] . This method, however, requires laborious sample preparation including extraction and derivatization steps, frequently with overnight incubation, followed by more than10 minute chromatographic separations per sample to resolve structurally related compounds. During recent years, LC-MS/MS has been rapidly replacing GC-MS in clinical laboratories due to its relative methodological simplicity [13] [14] [15] .
This new method provides both accurate and precise determination of MMA in serum and plasma samples. The correlations of our results with other methods as well as accumulated results of clinical samples justify the use of published data [6, 9] 
